Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708383 · ClinicalTrials.gov registry record · NA
in Vitro Fertilization (IVF) Media Protein and Live Birth Rates
A NA study, sponsored by Texas Health Resources.
- Completed
- Registry status
- NA
- Development phase
- 538
- Enrollment target
NCT00708383: Completed NA study, sponsored by Texas Health Resources.
NCT00708383 is a NA study that has completed, run by Texas Health Resources. The registered enrollment target is 538 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00708383, a NA study, has completed, sponsored by Texas Health Resources.
- COMPLETED
- Registry status
- NA
- Development phase
- 538 participants
- Enrollment target
Study Summary
Human conception in vivo occurs in a complex milieu that includes proteins. It has been speculated that the addition of proteins more complex than human serum albumin to culture media may improve IVF outcomes. Whether the expense, labor and risk of adding additional human-derived protein to IVF media are warranted is a question unanswered. Patients, undergoing routine IVF or ICSI, will be assigned to one of two treatment groups in a randomized, prospective clinical trial . Embryos will be cultured in either media supplemented with human serum albumin (HSA) as a solitary protein supplement or in media supplemented with HSA + SSS from the 2-PN stage until the time of embryo transfer. Clinical endpoints monitored will be implantation rate, clinical pregnancy rate and live birth rate. It is expected that the supplementation of commercial embryo culture media containing HSA with the more complex protein source, SSS, will result in an overall increase in implantation, clinical pregnancy, and live birth rates. In the balance, protein enrichment of media may represent opportunities to simultaneously increase the live birth rate and reduce the incidence of multiple gestations.
Interventions
- OTHER 10% SSS embryo culture medium protein supplementation
- OTHER 0.5% HSA embryo culture medium protein supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-11 |
| Phase | NA |
What the finished NCT00708383 record still lists
NCT00708383 is an interventional study that assigns participants to a tested intervention. The registered 538 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which 10% SSS embryo culture medium protein supplementation is the first listed.
NCT00708383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00708383 about?
NCT00708383 is a clinical study titled "in Vitro Fertilization (IVF) Media Protein and Live Birth Rates". Human conception in vivo occurs in a complex milieu that includes proteins. It has been speculated that the addition of proteins more complex than human serum albumin to culture media may improve IVF outcomes. Whether the expense, labor and risk of adding additional human-derived protein to IVF medi...
What is the current status of trial NCT00708383?
This trial is currently completed. It is a NA study. The enrollment target is 538 participants. The study started on 2001-09. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00708383?
The interventions under investigation include: 10% SSS embryo culture medium protein supplementation (OTHER), 0.5% HSA embryo culture medium protein supplementation (OTHER).
Who is sponsoring clinical trial NCT00708383?
This trial is sponsored by Texas Health Resources, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00708383's enrollment target sits among peer trials
538 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03772028 · 538 participants · Phase 3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT06538038 · 538 participants
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- NCT05880004 · 537 participants · NA
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia